Search Result

Isoforms Recommended:	PLK1

Results for "

PLK-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Polo-like Kinase (PLK) (82) Akt (2) Androgen Receptor (1) Antibiotic (2) Apoptosis (23) Aurora Kinase (1) Autophagy (5) Bacterial (1) Bcl-2 Family (3) c-Myc (3) Caspase (1) CDK (4) DAPK (2) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (9) ERK (1) Ferroptosis (1) IKK (1) JAK (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (3) Microtubule/Tubulin (2) Mitosis (1) MMP (1) Mps1 (2) mTOR (1) Na+/K+ ATPase (1) Necroptosis (1) NEKs (3) NF-κB (1) Organoid (2) p38 MAPK (1) PAK (1) PARP (1) PI3K (5) PI5P4K (1) PIN1 (1) PROTACs (3) RAR/RXR (3) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Small Interfering RNA (siRNA) (3) STAT (2) VRK (1)
By Research Areas:	Cancer (90) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	Azide (1) Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Polo-like Kinase (PLK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10197

Wortmannin 160+ Cited Publications SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[1] .

HY-12137

Volasertib 30+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[1] .

HY-15828

Onvansertib 5+ Cited Publications NMS-1286937; NMS-P937	Polo-like Kinase (PLK) Apoptosis	Cancer
NMS-1286937 is a potent, selective and orally available *PLK1* inhibitor, with an IC₅₀ of 2 nM.

HY-50698

BI 2536 55+ Cited Publications	Polo-like Kinase (PLK) Epigenetic Reader Domain Apoptosis	Cancer
BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively ^[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

HY-12037A

Rigosertib 5+ Cited Publications ON-01910	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle ^[1] . Rigosertib is a selective and non-ATP-competitive inhibitor of *PLK1* with an IC₅₀ of 9 nM .

HY-50877

GSK461364 15+ Cited Publications GSK461364A	Polo-like Kinase (PLK)	Cancer
GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a K_i value of 2.2 nM.

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts ^[1].

HY-W286743

Nε-(Carboxymethyl)-L-lysine 1 Publications Verification CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Polo-like Kinase (PLK) ERK NF-κB	Cancer
Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of *PLK1* and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties ^[1] .

HY-12045

HMN-214 3 Publications Verification IVX-214	Polo-like Kinase (PLK)	Cancer
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

HY-15161

Ro3280 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
Ro3280 is a potent, highly selective inhibitor of *PLK1* with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

HY-11003

GW843682X 5+ Cited Publications GW843682	Polo-like Kinase (PLK)	Cancer
GW843682X is a selective, ATP-competitive inhibitor of *PLK1* and *PLK3, with IC₅₀*s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other kinases.

HY-147298

Plogosertib 1 Publications Verification CYC140	Polo-like Kinase (PLK)	Cancer
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive *PLK1* inhibitor (IC₅₀: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers ^[1] .

HY-112356

Scytonemin	Apoptosis Reactive Oxygen Species (ROS) Polo-like Kinase (PLK)	Inflammation/Immunology Cancer
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics ^[1] .

HY-15155

MLN0905 5 Publications Verification	Polo-like Kinase (PLK)	Cancer
MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC₅₀ value of 2 nM. MLN0905 can be used for the research of cancer ^[1] .

HY-12134

Poloxin 3 Publications Verification	Polo-like Kinase (PLK)	Cancer
Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC₅₀ of appr 4.8 μM.

HY-172737

RP-1664	Polo-like Kinase (PLK)	Cancer
RP-1664 is a selective and orally active *PLK4* inhibitor with an IC₅₀ of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of *PLK4* and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research ^[1][2].

HY-13994

Mps1-IN-2	Mps1 Polo-like Kinase (PLK)	Cancer
Mps1-IN-2 is a potent, selective and ATP-competitive dual *Mps1/Plk1* inhibitor, with an IC₅₀ and a K_d of 145 nM and 12 nM for Mps1 and a K_d of 61 nM for Plk1.

HY-108597

TC-S 7005 4 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively ^[1].

HY-102069

3MB-PP1	Polo-like Kinase (PLK) CDK DAPK	Others
3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC₅₀=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division ^[1] .

HY-15158

SBE13 Hydrochloride	Polo-like Kinase (PLK) Autophagy Apoptosis	Cancer
SBE13 Hydrochloride is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-151986

FOXM1-IN-1	DNA/RNA Synthesis	Cancer
FOXM1-IN-1 is a potent *FOXM1* inhibitor with an IC₅₀ value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein ^[1].

HY-139188

CC260	PI5P4K	Metabolic Disease Cancer
CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with K_is of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research ^[1].

HY-12037

Rigosertib sodium 5+ Cited Publications ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle ^[1] . Rigosertib sodium is a selective and non-ATP-competitive inhibitor of *PLK1* with an IC₅₀ of 9 nM .

HY-116423

JH295	NEKs	Cancer
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint ^[1]. JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13647

HMN-176	Polo-like Kinase (PLK) Mitosis	Cancer
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.

HY-12137A

Volasertib trihydrochloride 30+ Cited Publications BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models ^[1] .

HY-150259

MDEG-541	PROTACs c-Myc	Cancer
MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein ^[1].

HY-15159

Cyclapolin 9	Polo-like Kinase (PLK)	Cancer
Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 500 nM. Cyclapolin 9 is inactive against other kinases ^[1] .

HY-158031

PLK1/BRD4-IN-5	Apoptosis Polo-like Kinase (PLK) Epigenetic Reader Domain	Cancer
PLK1/BRD4-IN-5 (Compound SC10) is an orally active *PLK1* and BRD4 inhibitor with IC₅₀ values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research ^[1].

HY-160558

PLK1/BRD4-IN-3	Epigenetic Reader Domain Polo-like Kinase (PLK)	Cancer
PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 inhibits BRD4-BD1, PLK1 and BRDT-BD1, with IC₅₀s of 0.059, 0.127 and 0.245 μM, respectively ^[1].

HY-114302

CCB02 1 Publications Verification	Microtubule/Tubulin	Cancer
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 ^[1].

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 ^[1].

HY-159493

BI2536-PEG2-Halo	Polo-like Kinase (PLK)	Cancer
BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC₅₀=23 nM), exhibits selective toxicity against p53 mutant cancer cells ^[1].

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, *LARP1-mTOR, PI3K/Akt/Snail* and *PLK1* pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models ^[1] .

HY-148974

PLK1-IN-5	Polo-like Kinase (PLK)	Cancer
PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4) ^[1].

HY-173233

PLK1-IN-14	Polo-like Kinase (PLK)	Cancer
PLK1-IN-14 (Compound Hit-4) is a selective *PLK1* inhibitor. It has an IC₅₀ of 22.61 pM against *PLK1* and an IC₅₀ of 0.09 nM for inhibiting the proliferation of DU - 145 prostate cancer cells. PLK1-IN-14 can be used in the research of prostate cancer ^[1].

HY-169579

PLK1-IN-11	Polo-like Kinase (PLK)	Cancer
PLK1-IN-11 (Cluster 4, 16953209) is a *PLK1* inhibitor, with IC₅₀ of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma ^[1].

HY-126249

AAPK-25	Aurora Kinase Polo-like Kinase (PLK) Apoptosis	Cancer
AAPK-25 is a potent and selective *Aurora/PLK* dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 ^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM ^[1].

HY-114461B

(3S,17S)-FD-895	Drug Derivative DNA/RNA Synthesis	Cancer
(3S,17S)-FD-895 a FD-895 (HY-114461) analogue, is a spliceosome modulator. (3S,17S)-FD-895 inhibits cancer cell growth and exhibits gene-selective splice modulatory activity. (3S,17S)-FD-895 can be used for the research of colorectal carcinoma ^[1].

HY-149085

XS-060	RAR/RXR	Cancer
XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting *pRXRα-PLK1* interaction*. XS-060 inhibits p-RXRα interaction with PLK1* but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK1 at the centrosome ^[1] .

HY-N8692

Dihydrobaicalein	Polo-like Kinase (PLK) VRK	Cancer
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* ^[1].

HY-146792

PLK1-IN-4	Polo-like Kinase (PLK)	Cancer
PLK1-IN-4 is a potent and selective *PLK1* inhibitor with IC₅₀ < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma ^[1].

HY-149100

PLK1-IN-6	Polo-like Kinase (PLK) Epigenetic Reader Domain	Cancer
PLK1-IN-6 is a potent and selective *PLK1* inhibitor, with an IC₅₀ of 0.45 nM. PLK1-IN-6 shows significant anti-proliferative activities against cancer cells ^[1].

HY-149086

BPA-B9	RAR/RXR Apoptosis PARP Bcl-2 Family	Cancer
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. BPA-B9 has excellent RXRα-binding affinity (K_D=39.29 ± 1.12 nM). BPA-B9 inhibits the proliferation of cancer cells by inducing mitotic arrest and cell apoptosis ^[1].

HY-164955

*TTK/PLK1-IN-1*	Mps1 Polo-like Kinase (PLK)	Cancer
TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC₅₀ of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC ^[1].

HY-172364

PLK1-IN-12	Polo-like Kinase (PLK)	Cancer
PLK1-IN-12 is a highly selective and orally active *PLK1* inhibitor with an IC₅₀ of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC₅₀: >10000 nM) and PLK3 (IC₅₀: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research ^[1].

HY-173212

PLK1-IN-13	Polo-like Kinase (PLK) c-Myc Apoptosis	Cancer
PLK1-IN-13 is a selective and orally active *PLK1* inhibitor (IC₅₀: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC₅₀: 12.72 nM) and PLK3 (IC₅₀: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) ^[1].

HY-161521

PLK1-IN-10	Polo-like Kinase (PLK)	Cancer
PLK1-IN-10 (Compound 4Bb) is an orally active *PLK1* PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death ^[1].

HY-172880

PLK1-IN-15	Polo-like Kinase (PLK) Apoptosis	Cancer
PLK1-IN-15 (Compound 7n) is a PLK1 inhibitor (IC₅₀: 38.5 nM). PLK1-IN-15 exhibits antiproliferative activity against HepG2, Huh7, H1299 and A549 cells (IC₅₀: 2.03, 2.08, 4.79 and 17.11 μM, respectively). PLK1-IN-15 induces cell cycle arrest at the G2/M phase and apoptosis, and has anticancer activity ^[1].

HY-50698G

BI 2536	Polo-like Kinase (PLK) Apoptosis Epigenetic Reader Domain	Cancer
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively ^[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

Cat. No.	Product Name	Type

HY-W286743

Nε-(Carboxymethyl)-L-lysine

1 Publications Verification

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties ^[1] .

HY-50698G

BI 2536	Biochemical Assay Reagents
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively ^[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

Cat. No.	Product Name	Target	Research Area

HY-180989

*PROTAC PLK1* Degrader-2**	PROTACs Polo-like Kinase (PLK) Apoptosis	Cancer
PROTAC PLK1 Degrader-2 (Compound NC1) is a PLK1 PROTAC degrader with an K_d of 6.06 μM. PROTAC PLK1 Degrader-2 significantly inhibits the proliferation of HeLa cells, induces cell cycle arrest and apoptosis. PROTAC PLK1 Degrader-2 exhibits significant anti-tumor activity in a HeLa cell xenograft tumor mouse model. PROTAC PLK1 Degrader-2 can be used for the study of cervical cancer.

HY-180991

Arg12-AHX	E3 Ligase Ligand-Linker Conjugates	Cancer
Arg12-AHX is a synthetic E3 ligase-ligand conjugate that can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). PROTAC PLK1 Degrader-2 is a PLK1 PROTAC degrader with anti-tumor activity ^[1].

HY-180990

POI ligand-3	Ligands for Target Protein for PROTAC Polo-like Kinase (PLK)	Cancer
POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989) ^[1].

HY-P11631

Arg12	Ligands for E3 Ligase	Cancer
Arg12, a 12-amino acid peptide sequence, is an E3 ubiquitin ligase ligand. Arg12 can be used to synthesize PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). Arg12 can also act as a cell transmembrane peptide (CPP), facilitating the entire molecule to enter the cell ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10197

Wortmannin 160+ Cited Publications SL-2052; KY-12420	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[1] .

HY-112356

Scytonemin	Alkaloids Microorganisms Classification of Application Fields Sunscreen Cosmetic Research Indole Alkaloids Source Classification	Apoptosis Reactive Oxygen Species (ROS) Polo-like Kinase (PLK)
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics ^[1] .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Structural Classification Animals Classification of Application Fields Other Diseases Disease Research Fields Steroids Source Classification	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, *LARP1-mTOR, PI3K/Akt/Snail* and *PLK1* pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models ^[1] .

HY-N8692

Dihydrobaicalein	Structural Classification Flavonoids Labiatae Flavonones Plants Medicago truncatula Gaertn. Source Classification	Polo-like Kinase (PLK) VRK
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* ^[1].

HY-10197R

Wortmannin (Standard) SL-2052 (Standard); KY-12420 (Standard)	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Organoid Reference Standards PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively ^[1] .

HY-N13795

3,4,3'-Tri-O-methylflavellagic acid	Terminalia paniculata Roth Structural Classification Combretaceae Phenols Polyphenols Plants Source Classification	Polo-like Kinase (PLK) Microtubule/Tubulin
3,4,3'-Tri-O-methylflavellagic acid is a flavonoid inhibitor that targets αβ-tubulin (colchicine binding site) and polo-like kinase-1 (PLK-1), and can be isolated from the roots of Anogeissus leiocarpus. 3,4,3'-Tri-O-methylflavellagic acid interferes with microtubule assembly dynamics and kinase activity, exhibiting anti-cancer cell proliferation and potent anti-nociceptive effects ^[1].

Recombinant Proteins Recommended:

Species:	Human (3) Mouse (1)
Tag:	His (3) Tag Free (1)
Source:	sf9 insect cells (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705858

	PLK1 Protein, Human (233a.a) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	E. coli

HY-P76550

	PLK1 Protein, Human (Active, sf9, His) 3 Publications Verification Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	Sf9 insect cells
	PLK1 is a serine/threonine protein kinase that centrally coordinates key functions during the M phase of the cell cycle. It regulates centrosome maturation, spindle assembly, cohesin removal, inactivates APC/C inhibitors, and controls mitotic exit and cytokinesis. PLK1 Protein, Human (sf9, His) is the recombinant human-derived PLK1 protein, expressed by Sf9 insect cells , with N-10*His labeled tag.

HY-P73706

	PLK1 Protein, Mouse (Active, sf9, His) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Mouse	Sf9 insect cells
	PLK1 is a serine/threonine protein kinase that centrally coordinates key functions during the M phase of the cell cycle. It regulates centrosome maturation, spindle assembly, cohesin removal, inactivates APC/C inhibitors, and controls mitotic exit and cytokinesis. PLK1 Protein, Mouse (sf9, His) is the recombinant mouse-derived PLK1 protein, expressed by Sf9 insect cells, with N-His labeled tag.

HY-P705859

	PLK1 Protein, Human (Inactive, T210V, sf9, His) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (3) Rabbit (4)
Reactivity:	Human (7) Rat (6) Mouse (4) Monkey (2)
Application:	IHC-P (4) ICC/IF (4) IP (3) WB (7) FC (3) ELISA (3)
Isotype:	IgG (4) IgG1 (2)
Conjugation:	Non-conjugated (7)
Clonality:	Monoclonal (5) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86183

	PLK1 Antibody (YA5875) Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PLK1 Antibody (YA5875) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P85720

	PLK1 Antibody (YA5412) Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13;	IHC-P, WB	Human, Mouse, Rat
	PLK1 Antibody (YA5412) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PLK1.

HY-P80972

	PLK1 Antibody (YA843) PLK1; PLK; Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13	WB, ICC/IF, IP	Human, Rat
	PLK1 Antibody (YA843) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P80972A

	PLK1 Antibody (YA843)(PBS only) PLK1; PLK; Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13	WB, ICC/IF, IP	Human, Rat
	PLK1 Antibody (YA843) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P84387

	PLK1 Antibody (YA4084) PLK; STPK13	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	PLK1 Antibody (YA4084) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLK1.

HY-P84387A

	PLK1 Antibody (YA4084)(PBS only) PLK; STPK13	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	PLK1 Antibody (YA4084) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLK1.

HY-P80474

	*Phospho-PLK1* (Thr210) Antibody (YA161)** 1 Publications Verification	WB, ICC/IF, FC	Human
	Phospho-PLK1 (Thr210) Antibody (YA161) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PLK1 (Thr210).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint ^[1]. JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159493

BI2536-PEG2-Halo		Azide
BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC₅₀=23 nM), exhibits selective toxicity against p53 mutant cancer cells ^[1].

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint ^[1]. JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Targets Recommended: Polo-like Kinase (PLK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50698G

BI 2536	Polo-like Kinase (PLK) Apoptosis Epigenetic Reader Domain	Cancer
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively ^[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PLK-1

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products